KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Inventory (2017 - 2026)

Aquestive Therapeutics has reported Inventory over the past 9 years, most recently at $6.2 million for Q4 2025.

  • For Q4 2025, Inventory rose 2.07% year-over-year to $6.2 million; the TTM value through Dec 2025 reached $6.2 million, up 2.07%, while the annual FY2025 figure was $6.2 million, 2.07% up from the prior year.
  • Inventory for Q4 2025 was $6.2 million at Aquestive Therapeutics, down from $7.9 million in the prior quarter.
  • Over five years, Inventory peaked at $8.1 million in Q2 2025 and troughed at $2.8 million in Q1 2021.
  • A 5-year average of $5.9 million and a median of $6.4 million in 2022 define the central range for Inventory.
  • Biggest five-year swings in Inventory: decreased 11.69% in 2021 and later skyrocketed 134.89% in 2022.
  • Year by year, Inventory stood at $4.0 million in 2021, then soared by 43.14% to $5.8 million in 2022, then grew by 17.11% to $6.8 million in 2023, then fell by 10.71% to $6.0 million in 2024, then rose by 2.07% to $6.2 million in 2025.
  • Business Quant data shows Inventory for AQST at $6.2 million in Q4 2025, $7.9 million in Q3 2025, and $8.1 million in Q2 2025.